Lack of insulin could affect 40 million diabetics by 2030
Insulin use is expected to rise 20 per cent by 2030, and many people who need it for Type 2 diabetes won’t have access, a study from Stanford University suggests.
Globally, 511 million adults are expected to have Type 2 diabetes in 12 years, up from 406 million this year, the study found.
More than half of those people come from China, India and the U.S.
The study found 79 million people worldwide will require insulin to treat the disease, but only 38 million will have access.
“These estimates suggest that current levels of insulin access are highly inadequate compared to projected need, particularly in Africa and Asia, and more efforts should be devoted to overcoming this looming health challenge,” Sanjay Basu, lead author on the study and an assistant professor of medicine at Stanford, said in a statement.
The study was published Tuesday in the journal The Lancet Diabetes & Endocrinology.
It used data from the International Diabetes Federation and 14 studies, which represent more than 60 per cent of people with Type 2 diabetes worldwide.
Researchers are urging governments to make insulin more available and affordable to boost access, especially in Africa, where global access could lead to a sevenfold increase in insulin use, researchers said. The study also predicts using a higher treatment target for A1C levels, a measure for tracking blood glucose, could reduce the number of people who need to use insulin.
Authors warn the results come with several caveats, most notably estimates don’t consider how changes in diet and physical activity could affect how much insulin would be required.
In a commentary attached to the study, Hertzel Gerstein, an endocrinologist and professor at McMaster University in Hamilton, Ont., said predictions made in the study should be viewed with caution.
“They are based on mathematical models that are in turn based on other mathematical models,” Gerstein said. “They are also based on various assumptions, including that Type 2 diabetes prevalence will continue to increase linearly.”
A big concern with accessibility to insulin is high costs. In May, William Cefalu, the chief scientific, medical and mission officer with the American Diabetes Association, testified before the Senate to discussing insulin prices, which tripled between 2002 and 2013.
“Many people with diabetes are experiencing increased burdens due to the high out-of-pocket costs for insulin, which can negatively impact their lives and health,” Cefalu said in a statement in May.